Orthometrix, Inc. Announces 67% Increase in Quarterly Sales and Launches the Vibraflex(R) Home Edition, a New Patented Whole Bod

  
    
  
  
    
      ORTHOMETRIX, INC. (OTCBB: OMRX) announced today its 
      financial results for the third quarter ended September 30, 2006.
    
    
      Revenue for the third quarter ended September 30, 2006 increased by 67% 
      to $507,368, compared with $302,981 for the third quarter ended 
      September 30, 2005. Gross Margin for the third quarter ended September 
      30, 2006 increased to 64%, compared with 55% for the third quarter ended 
      September 30, 2005. The net loss for the third quarter of 2006 decreased 
      to $393,335, compared with a 2005 third quarter net loss of $564,649.
    
    
      Revenue for the nine month period ended September 30, 2006 increased by 
      69% to $1,967,390, compared with $1,165,445 for the nine month period 
      ended September 30, 2005. Gross Margin for the nine month period ended 
      September 30, 2006 increased to 65% compared with 59% for the nine month 
      period ended September 30, 2005. The net loss for the first nine months 
      of 2006 decreased to $1,042,579 compared with a net loss of $1,523,248 
      for the first nine months of 2005.
    
    
      The Company also announced that it has launched the VibraFlex® 
      Home Edition, its first Whole Body Vibration model designed specifically 
      for the home market. The VibraFlex® is a 
      patented motorized exercise system used to facilitate exercise by 
      individuals with conditions affecting muscle, tendons and ligaments; 
      poor muscle strength and coordination; and poor blood circulation 
      (spinal cord injuries, Osteoarthritis, Incontinence, Diabetes, and 
      Parkinson’s disease). In 2001, the Company 
      received from the U.S. Food & Drug Administration (FDA) a written 
      acknowledgement that devices using this technology may be marketed as 
      Class I devices intended for exercise in connection with such 
      conditions. After being used primarily in rehabilitation and physical 
      therapy, the VibraFlex® started to penetrate 
      the sports and the fitness markets. Today, units are used by star 
      athletes and major professional teams (NBA, MLB, NFL, etc…), 
      as well as fitness clubs (New York Sports Clubs, Gold’s 
      Gym, etc…). Earlier this year, the VibraFlex® 
      500 was named one of three overall best new product winners out of over 
      300 new products as voted by Professional Golf Association (PGA) members 
      and buyers at the 2006 PGA Merchandise Show in Orlando, Florida.
    
    
      Reynald Bonmati, Chairman and Chief Executive Officer of Orthometrix, 
      commented, “We continue to be pleased with 
      our sales for the first nine month of 2006 which already amount to 130% 
      of the sales we booked for the entire year 2005. Our VibraFlex® 
      line of patented exercise equipment for fitness and wellness has been 
      the main driver of such sales increase as Whole Body Vibration is 
      getting better known worldwide. As VibraFlex® 
      commercial models started to be purchased for their home gym by 
      customers who can afford their relatively high prices, we have developed 
      the VibraFlex® Home Edition, a new version 
      specially designed for the home market and priced at 1/3 of the 
      commercial models. Our goal is to make the powerful VibraFlex® 
      technology accessible to the public which is becoming increasingly 
      fitness conscious.”
    
    
      Orthometrix, Inc. markets, sells and services several musculoskeletal 
      product lines used in pharmaceutical research, diagnostic and monitoring 
      of bone and muscle disorders, sports medicine, rehabilitative medicine, 
      physical therapy and pain management.
    
    
      Our Web addresses are www.orthometrix.net, 
      www.vibraflex.com and www.orbasone.com.
    
    
      “Safe Harbor” 
      Statement under the Private Securities Litigation Reform Act of 1995: The 
      statements which are not historical facts contained in this release are 
      forward looking statements that involve risk and uncertainties, 
      including, but not limited to, any effect on future financial results 
      from efforts to broaden the Company’s 
      position in the rehabilitation, physical therapy and musculoskeletal 
      markets, any potential impact on sales of VibraFlex in North America and 
      other risks detailed in the documents periodically filed with the 
      Securities and Exchange Commission, specifically the most recent reports 
      on Forms 10-KSB and 10-QSB. These risks and uncertainties could cause 
      actual results to differ materially from those expected and/or contained 
      in the forward-looking statements. Any forward-looking statement made in 
      this release is made as of the date of this release and the Company 
      assumes no obligation, subject to applicable law, to update such 
      forward-looking statement.
    
    
      
        
          Orthometrix, Inc.
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
      
      
        
          Consolidated Statement of Operations
        
        
        
        
        
        
        
        
        
      
      
        
          (unaudited)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
      
      
        
        
        
        
        
        
        
        
        
        
        
          
            Nine months ended
          
          
            September 30,
          
        
        
        
        
          Three months ended

          
            September 30,
          
        
      
      
        
        
        
        
        
        
        
        
        
        
        
          2006 
        
        
        
        
          2005 
        
        
        
        
          2006 
        
        
        
        
          2005 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Revenue
        
        
        
        
        
        
        
        
          $1,967,390 
        
        
        
        
          $1,165,445 
        
        
        
        
          $507,368 
        
        
        
        
          $302,981 
        
      
      
        
          Cost of revenue
        
        
        
        
        
        
        
        
          689,956 
        
        
        
        
          479,744 
        
        
        
        
          180,907 
        
        
        
        
          135,762 
        
      
      
        
          Gross profit
        
        
        
        
        
        
        
        
          $1,277,436 
        
        
        
        
          $685,701 
        
        
        
        
          $326,461 
        
        
        
        
          $167,219 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Sales and marketing expense
        
        
        
        
        
        
          1,236,818 
        
        
        
        
          889,712 
        
        
        
        
          372,205 
        
        
        
        
          343,938 
        
      
      
        
          General and administrative expense
        
        
        
        
          877,858 
        
        
        
        
          969,436 
        
        
        
        
          208,681 
        
        
        
        
          303,226 
        
      
      
        
          Research and development expense
        
        
        
        
          104,664 
        
        
        
        
          313,109 
        
        
        
        
          37,135 
        
        
        
        
          84,905 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Operating loss
        
        
        
        
        
        
        
        
          ($941,904)
        
        
        
        
          ($1,486,556)
        
        
        
        
          ($291,560)
        
        
        
        
          ($564,850)
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Interest expense
        
        
        
        
        
        
        
        
          (218,093)
        
        
        
        
          (40,340)
        
        
        
        
          (121,954)
        
        
        
        
          (11)
        
      
      
        
          Interest income
        
        
        
        
        
        
        
        
          2,187 
        
        
        
        
          3,648 
        
        
        
        
          179 
        
        
        
        
          212 
        
      
      
        
          Other income (expense)
        
        
        
        
        
        
        
        
          115,231 
        
        
        
        
          - 
        
        
        
        
          20,000 
        
        
        
        
          - 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Loss before income taxes
        
        
        
        
        
        
          ($1,042,579)
        
        
        
        
          ($1,523,248)
        
        
        
        
          ($393,335)
        
        
        
        
          ($564,649)
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Income tax
        
        
        
        
        
        
        
        
          - 
        
        
        
        
          - 
        
        
        
        
          -- 
        
        
        
        
          - 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Net loss
        
        
        
        
        
        
        
        
          ($1,042,579)
        
        
        
        
          ($1,523,248)
        
        
        
        
          ($393,335)
        
        
        
        
          ($564,649)
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Basic and diluted weighted average shares
        
        
        
        
          44,366,457 
        
        
        
        
          41,472,122 
        
        
        
        
          44,355,303 
        
        
        
        
          43,470,248 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Basic and diluted loss per share
        
        
        
        
          ($0.02)
        
        
        
        
          ($0.04)
        
        
        
        
          ($0.01)
        
        
        
        
          ($0.01)
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Selected Balance Sheet Data:
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
      
      
        
          (unaudited)
        
        
        
        
        
        
        
        
        
        
          September 30,
        
        
        
        
          
            December
          
          
            31,
          
        
        
        
        
        
        
        
        
        
      
      
        
        
        
        
        
        
        
        
        
        
        
          2006 
        
        
        
        
          2005 
        
        
        
        
        
        
        
        
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Cash and cash equivalents
        
        
        
        
        
        
          $33,077 
        
        
        
        
          $22,861 
        
        
        
        
        
        
        
        
        
      
      
        
          Other current assets
        
        
        
        
        
        
        
        
          956,312 
        
        
        
        
          454,167 
        
        
        
        
        
        
        
        
        
      
      
        
          Long term assets
        
        
        
        
        
        
        
        
          101,892 
        
        
        
        
          53,694 
        
        
        
        
        
        
        
        
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
        
        
          Total assets
        
        
        
        
        
        
          $1,091,211 
        
        
        
        
          $530,722 
        
        
        
        
        
        
        
        
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Bank Borrowings
        
        
        
        
        
        
        
        
          $350,000 
        
        
        
        
          $330,000 
        
        
        
        
        
        
        
        
        
      
      
        
          Other current liabilities
        
        
        
        
        
        
          1,234,666 
        
        
        
        
          816,449 
        
        
        
        
        
        
        
        
        
      
      
        
          Note payable - net
        
        
        
        
        
        
        
        
          918,226 
        
        
        
        
          183,069 
        
        
        
        
        
        
        
        
        
      
      
        
          Total stockholders' equity (deficit)
        
        
        
        
        
        
          (1,411,681)
        
        
        
        
          (798,796)
        
        
        
        
        
        
        
        
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
        
        
          Total liabilities and equity
        
        
        
        
          $1,091,211 
        
        
        
        
          $530,722 
        
        
        
        
        
        
        
      
    
  
ORTHOMETRIX, INC. (OTCBB: OMRX) announced today its financial
results for the third quarter ended September 30, 2006.

   Revenue for the third quarter ended September 30, 2006 increased
by 67% to $507,368, compared with $302,981 for the third quarter ended
September 30, 2005. Gross Margin for the third quarter ended September
30, 2006 increased to 64%, compared with 55% for the third quarter
ended September 30, 2005. The net loss for the third quarter of 2006
decreased to $393,335, compared with a 2005 third quarter net loss of
$564,649.

   Revenue for the nine month period ended September 30, 2006
increased by 69% to $1,967,390, compared with $1,165,445 for the nine
month period ended September 30, 2005. Gross Margin for the nine month
period ended September 30, 2006 increased to 65% compared with 59% for
the nine month period ended September 30, 2005. The net loss for the
first nine months of 2006 decreased to $1,042,579 compared with a net
loss of $1,523,248 for the first nine months of 2005.

   The Company also announced that it has launched the VibraFlex(R)
Home Edition, its first Whole Body Vibration model designed
specifically for the home market. The VibraFlex(R) is a patented
motorized exercise system used to facilitate exercise by individuals
with conditions affecting muscle, tendons and ligaments; poor muscle
strength and coordination; and poor blood circulation (spinal cord
injuries, Osteoarthritis, Incontinence, Diabetes, and Parkinson's
disease). In 2001, the Company received from the U.S. Food & Drug
Administration (FDA) a written acknowledgement that devices using this
technology may be marketed as Class I devices intended for exercise in
connection with such conditions. After being used primarily in
rehabilitation and physical therapy, the VibraFlex(R) started to
penetrate the sports and the fitness markets. Today, units are used by
star athletes and major professional teams (NBA, MLB, NFL, etc...), as
well as fitness clubs (New York Sports Clubs, Gold's Gym, etc...).
Earlier this year, the VibraFlex(R) 500 was named one of three overall
best new product winners out of over 300 new products as voted by
Professional Golf Association (PGA) members and buyers at the 2006 PGA
Merchandise Show in Orlando, Florida.

   Reynald Bonmati, Chairman and Chief Executive Officer of
Orthometrix, commented, "We continue to be pleased with our sales for
the first nine month of 2006 which already amount to 130% of the sales
we booked for the entire year 2005. Our VibraFlex(R) line of patented
exercise equipment for fitness and wellness has been the main driver
of such sales increase as Whole Body Vibration is getting better known
worldwide. As VibraFlex(R) commercial models started to be purchased
for their home gym by customers who can afford their relatively high
prices, we have developed the VibraFlex(R) Home Edition, a new version
specially designed for the home market and priced at 1/3 of the
commercial models. Our goal is to make the powerful VibraFlex(R)
technology accessible to the public which is becoming increasingly
fitness conscious."

   Orthometrix, Inc. markets, sells and services several
musculoskeletal product lines used in pharmaceutical research,
diagnostic and monitoring of bone and muscle disorders, sports
medicine, rehabilitative medicine, physical therapy and pain
management.

   Our Web addresses are www.orthometrix.net, www.vibraflex.com and
www.orbasone.com.

   "Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements which are not historical facts
contained in this release are forward looking statements that involve
risk and uncertainties, including, but not limited to, any effect on
future financial results from efforts to broaden the Company's
position in the rehabilitation, physical therapy and musculoskeletal
markets, any potential impact on sales of VibraFlex in North America
and other risks detailed in the documents periodically filed with the
Securities and Exchange Commission, specifically the most recent
reports on Forms 10-KSB and 10-QSB. These risks and uncertainties
could cause actual results to differ materially from those expected
and/or contained in the forward-looking statements. Any
forward-looking statement made in this release is made as of the date
of this release and the Company assumes no obligation, subject to
applicable law, to update such forward-looking statement.

-0-
*T
Orthometrix, Inc.
Consolidated Statement of Operations
----------------------------------------------
(unaudited)
                         Nine months ended       Three months ended
                           September 30,            September 30,
                     ------------------------- -----------------------
                        2006         2005         2006        2005
                     ------------ ------------ ----------- -----------

Revenue               $1,967,390   $1,165,445    $507,368    $302,981
Cost of revenue          689,956      479,744     180,907     135,762
                     ------------ ------------ ----------- -----------
Gross profit          $1,277,436     $685,701    $326,461    $167,219

Sales and marketing
 expense               1,236,818      889,712     372,205     343,938
General and
 administrative
 expense                 877,858      969,436     208,681     303,226
Research and
 development expense     104,664      313,109      37,135      84,905

Operating loss         ($941,904) ($1,486,556)  ($291,560)  ($564,850)

Interest expense        (218,093)     (40,340)   (121,954)        (11)
Interest income            2,187        3,648         179         212
Other income
 (expense)               115,231            -      20,000           -
                     ------------ ------------ ----------- -----------

Loss before income
 taxes               ($1,042,579) ($1,523,248)  ($393,335)  ($564,649)

Income tax                     -            -          --           -
                     ------------ ------------ ----------- -----------

Net loss             ($1,042,579) ($1,523,248)  ($393,335)  ($564,649)
                     ============ ============ =========== ===========

Basic and diluted
 weighted average
 shares               44,366,457   41,472,122  44,355,303  43,470,248
                     ============ ============ =========== ===========

Basic and diluted
 loss per share           ($0.02)      ($0.04)     ($0.01)     ($0.01)
                     ============ ============ =========== ===========

Selected Balance
 Sheet Data:
-------------------
(unaudited)           September     December
                          30,         31,
                        2006         2005
                     ------------ ------------

Cash and cash
 equivalents             $33,077      $22,861
Other current
 assets                  956,312      454,167
Long term assets         101,892       53,694
                     ------------ ------------

    Total assets      $1,091,211     $530,722
                     ============ ============

Bank Borrowings         $350,000     $330,000
Other current
 liabilities           1,234,666      816,449
Note payable - net       918,226      183,069
Total stockholders'
 equity (deficit)     (1,411,681)    (798,796)
                     ------------ ------------

    Total
     liabilities and
     equity           $1,091,211     $530,722
                     ============ ============
*T